QMENTA Appoints Dr. Montserrat Barceló as Strategic Advisor to Support Global Growth and Enterprise Expansion

BARCELONA, Spain, March 11, 2026 — QMENTA, a neuroimaging AI company accelerating clinical trials and drug development, today named Dr. Montserrat Barceló as strategic advisor. The appointment adds a physician-executive with more than three decades of CRO leadership and enterprise commercial experience to QMENTA's advisory board.

Barceló spent much of her career at TFS HealthScience in Sweden, where as global COO, she led clinical trial delivery for more than 200 customers and managed a workforce of more than 750 professionals across 25 locations worldwide. She later worked for Veristat at its headquarters in Boston, directing international business operations and M&A integration.

Dr. Barceló's Background and CRO Leadership Experience

She currently sits on the board of KYMOS, advises U.K.-based trial technology company Trial Hub, and is an advisor and investor at IKI Health, an AI-powered SaaS platform in the longevity and digital health space.

Beyond her operating experience, Barceló co-founded WeRock Capital, a women-led angel investor group, and served as vice president of EjeCon, the Spanish Association of Women Executives and Board Members, a network that spans senior executives and CFOs across the European business community. That connectivity is expected to support QMENTA's enterprise go-to-market motions to engage with top-tier pharmaceutical sponsors.

"Montse understands how this industry actually works—how sponsors evaluate vendors, how procurement decisions get made, and what it takes to become a trusted long-term partner in complex clinical programs," said Vesna Prchkovska, CEO of QMENTA. "She understands what it takes to build the kind of enterprise relationships that turn pilots into long-term programs and how to position QMENTA so the right sponsors see us as a strategic partner, not just a vendor.

That commercial fluency, at this stage of our growth, is rare."

Vesna Prchkovska, CEO, QMENTA

"I have spent my career sitting on the other side of this table as a buyer, operator, and someone building global teams," Barceló said. "When I looked at what QMENTA has built in neuroimaging AI, and where the field is moving in biomarkers and the longevity economy, the fit was obvious. Barcelona is having a genuine moment in biotech, and I want to help make sure QMENTA is visible, both to the US and to Asia. This is a company worth betting on."

Dr. Montserrat Barceló, Strategic Advisor, QMENTA

A founding member of the Spanish Association of Women Executives and Board Members, she has long advocated for gender diversity in senior decision-making roles. Prchkovska noted that the appointment reflects a deliberate commitment to building a leadership structure that reflects those values.

In her advisory role, Barceló will work closely with Prchkovska and the QMENTA leadership team on growth strategy, enterprise positioning, governance, and international expansion — with a particular focus on the European and Asia-Pacific markets.

Resources:

To learn more about QMENTA's Imaging Hub and how it supports neuroimaging workflows across clinical trials, visit https://www.qmenta.com/imaging-hub.

Start a free trial at qmenta.com.

About QMENTA

QMENTA is a neuroimaging AI company that helps biopharma, CROs, and academic research centers streamline complex imaging clinical trials. Its cloud-native Imaging Hub eliminates fragmentation across imaging workflows by unifying data management, AI biomarker analysis, and central review in one compliant, off-the-shelf system—reducing site burden and accelerating imaging-driven decisions. The company's customers include Amylyx Pharmaceuticals, Alzamend Neuro, Cedars-Sinai, and Cleveland Clinic.

Media Contact

Frank Days

Marketing Director

QMENTA

frank.days@qmenta.com

+1 617-982-1370

Frequently Asked Questions

Who is Dr. Montserrat Barceló and what is her background?

Dr. Montserrat Barceló is a physician-executive with more than 30 years of experience in clinical research and CRO leadership. She spent much of her career at TFS HealthScience in Sweden, where as global COO she led clinical trial delivery for more than 200 customers and managed a workforce of more than 750 professionals across 25 locations worldwide. She later directed international business operations and M&A integration at Veristat, and currently sits on the board of KYMOS, advises Trial Hub, and serves as an advisor and investor at IKI Health.

What is QMENTA's advisory board and what role does it play?

QMENTA's advisory board brings clinical research, enterprise commercial, and scientific expertise to support the company's growth strategy, enterprise positioning, and international expansion. Advisors work closely with the CEO and leadership team on specific strategic objectives — in Dr. Barceló's case, this includes enterprise go-to-market motions, pharma partnership development, and expansion into European and Asia-Pacific markets.

What does QMENTA's strategic advisor appointment signal about the company's growth stage?

The appointment of a senior CRO executive and investor as a strategic advisor reflects QMENTA's focus on moving from early-stage vendor relationships to long-term enterprise programmes with top-tier pharmaceutical sponsors. The emphasis on someone who understands "how sponsors evaluate vendors, how procurement decisions get made, and what it takes to become a trusted long-term partner" signals a deliberate shift toward enterprise sales motion and multi-programme partnerships.

What markets is QMENTA targeting for expansion?

QMENTA is focused on enterprise expansion in both the US and European markets, with increasing attention to Asia-Pacific opportunities. Dr. Barceló's appointment specifically supports QMENTA's goal of increasing visibility among top-tier pharmaceutical sponsors in the US and Asia, building on existing relationships in the European life sciences market where the company was founded (Barcelona, Spain).

What is QMENTA's Imaging Hub?

QMENTA's Imaging Hub is a cloud-native medical imaging platform designed for neuroimaging clinical trials. It unifies data management (including PHI de-identification and DICOM handling), AI-powered biomarker analysis (50+ algorithms), blinded independent central review, and imaging trial management in a single compliant system. The platform is used by biopharma sponsors, CROs, and academic research centres globally, including Amylyx Pharmaceuticals, Cleveland Clinic, Cedars Sinai, and Alzamend Neuro.

About the author: Vesna Prchkovska, CEO, QMENTA